Protocol Ledger

NCT07910630 · Phase II · RECRUITING

A Study Evaluating the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) in Patients With Vitreomacular Traction

Interventional Phase II clinical trial protocol NCT07910630 sponsored by Jiangsu Jingze Biopharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-08 Enrollment: 48 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07910630
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07910630
Protocol FieldVerified Registry Value
NCT IdentifierNCT07910630
Consolidated Lead SponsorJiangsu Jingze Biopharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment48 participants (ESTIMATED)
Registered Start Date2026-09-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI